Images in Clinical Rheumatology

Rapid Dactylitis Resolution in a Patient With Psoriatic Arthritis After Treatment With Ustekinumab

Rápida resolución de la dactilitis en un paciente con artritis psoriásica tras tratamiento con ustekinumab

Alba Quesada Moreno, a,b,∗ Olga Martínez González, a Laura Pérez Garrido, a Carlos Montilla Morales a,b

a Servicio de Reumatología, Hospital Universitario de Salamanca, Salamanca, Spain
b Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

A R T I C L E   I N F O

Article history:
Received 6 September 2016
Accepted 21 November 2016
Available online xxx

We report the case of a 51-year-old man diagnosed in 2011 with polyarticular psoriatic arthritis with nail involvement. The disease was refractory to treatment with nonsteroidal anti-inflammatory drugs (NSAID) and synthetic disease-modifying antirheumatic drugs (DMARD) (methotrexate at 25 mg/week and salazopyrine at a dose of 500 mg/8 h). The decision was made to start biological therapy with tumor necrosis factor inhibitors (anti-TNF), following the recommendations of the European League Against Rheumatism.

Adalimumab was chosen as the first biological agent. However, after 2 years of treatment, the activity of the disease remained moderate (Disease Activity Score—erythrocyte sedimentation rate [DAS28-ESR] = 3.70); 3 tender joints and 3 swollen joints: right 4th metacarpophalangeal [MCP] joint, left 3rd MCP and left knee). In addition, he had painful dactylitis in the 4th toe of right foot (Fig. 1). Thus, treatment was begun with etanercept. Nevertheless, after 6 months of treatment, he continued to have high inflammatory activity (DAS28-ESR = 5.80; 4 tender joints and 4 swollen joints: right 4th MCP, left 3rd MCP and both knees). Therefore, treatment was started with certolizumab pegol, which he took for 6 months, although it failed to control the inflammatory activity (DAS28-ESR = 4.89; 4 tender joints—right 4th MCP, left 3rd MCP, left 4th proximal interphalangeal [PIP] joint and left knee—and 3 swollen joints: right 4th MCP, left 3rd MCP and left knee), and the dactylitis was not resolved.

Fig. 1. Dactylitis in 4th toe.

* Corresponding author.
E-mail address: a.quesada.moreno@gmail.com (A. Quesada Moreno).

Given the therapeutic failure with 3 anti-TNF-α agents, the decision was made to initiate treatment with ustekinumab. After 2 doses of ustekinumab, he achieved complete resolution of the dactylitis, with a significant improvement in the nail involvement (Fig. 2), and better control of the joint inflammatory activity.
Ustekinumab is a monoclonal antibody that inhibits the p-40 subunit of interleukin (IL)-12/IL-23, that has been found to be effective in all of the domains of psoriatic arthritis.1–3

The importance of this case lies in the rapid resolution of the dactylitis with ustekinumab, despite the fact that it had been found to be refractory to treatment with 3 anti-TNF agents.4–5 This incredible improvement may corroborate the importance of IL-23 in the development of dactylitis and the relevance of its inhibition for the treatment of this domain.

Ethical Disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflicts of Interest

The authors declare they have no conflicts of interest.

References